Mission Pharmacal

Focus: Mission Pharmacal is a private specialty pharmaceutical company based in San Antonio, TX, focused on small molecules and consumer products across hematology, neurology, and nephrology.

Hematology Neurology Nephrology

Profile data last refreshed 30m ago · AI intelligence enriched 3w ago

Funding Stage

PRIVATE

Open Jobs

9+1 this month

Stable — net +1 jobs in 30d

4 added, 3 removed. Backfill posture.

Should You Work at Mission Pharmacal?

AI assessment

Mission Pharmacal is a stable, niche operator with a profitable flagship asset but carries concentration risk and limited growth signals; best suited for candidates seeking a boutique environment over rapid advancement.

Why Work Here

THIOLA EC generates $23M in Part D spending with patent protection extending to 2038, providing revenue stability and a clear commercial anchor.

Data completeness

5/9 — Partial

Company HealthStrong

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Growing

Jobs increasing

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

THIOLA EC

Reducing and Complexing Thiol

$23M Part D

Peak12.0yr

Sole revenue driver for the company with nearly two decades of patent protection remaining.

Help build intelligence for Mission Pharmacal

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Portfolio spans multiple therapeutic areas (hematology, neurology, nephrology) with early-stage pipeline programs in Phase 1–3 development, offering exposure to R&D across disease areas.

Private, founder-led structure in a growing specialty market allows for entrepreneurial impact and potentially flatter organizational hierarchy than large pharma.

Watch Out For

Extreme revenue concentration—100% dependency on a single product (THIOLA EC) creates significant business risk if sales decline or regulatory status changes.
Minimal hiring activity (8 open roles) and no disclosed funding data suggest tight headcount planning and potential constraints on career progression or internal mobility.
Sparse pipeline maturity: only 4 active trials (1 Phase 3, 2 Phase 2, 1 Phase 1) and no disclosed PDUFA dates indicate limited near-term catalyst runway and uncertain R&D productivity.

Generated by Claude from Mission Pharmacal's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

THYROSHIELD

Not specified

Post-LOE

Legacy branded generic in post-LOE phase with no disclosed Part D revenue.

GABAPENTIN

Not specified

Post-LOE

Mature generic product with no disclosed commercial revenue.

THYROSAFE

Not specified

Post-LOE

Consumer-facing potassium iodide product in post-LOE phase.